Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Mitsubishi Tanabe to Pull Plug on Generics, Transfer Biz to Nipro in October
Mitsubishi Tanabe Pharma will pull out from the generic market as its board of directors on March 28 agreed to split off and transfer its generics and part of the long-listed product business to Nipro Corporation in October. Mitsubishi Tanabe…
To read the full story
Related Article
- Nipro Aims at 100 Billion Yen Sales for Pharma Biz by FY2020, Seeking No. 1 Spot among Research-Oriented Makers in Generic Field
October 5, 2017
- Mitsubishi Tanabe Eyes M&As for Post-Radicava Strategy in US: President
May 11, 2017
- Mitsubishi Tanabe’s Exit Shows Research-Driven Makers’ Generic Biz at Crossroads
March 31, 2017
BUSINESS
- Towa to Take Over Manufacturing of Otsuka’s LLPs in Cross-Sector Tie-Up
January 22, 2026
- Otsuka/Ionis’ HAE Drug Dawnzera Approved in Europe
January 22, 2026
- Shionogi to Lift Stake in ViiV to 21.7% as Pfizer Exits
January 21, 2026
- Fuji Pharma Earns Approval for High-Dose Stelara Biosimilar
January 21, 2026
- Kaken’s Hyperhidrosis Drug Ecclock Now Available in South Korea
January 20, 2026
As many as 47 new drug candidates are expected to win approval or secure NHI price listing in Japan in…
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…